Digital Analysis of Plasma miRNA populations in Pancreatic Cancer

Information

  • Research Project
  • 9411498
  • ApplicationId
    9411498
  • Core Project Number
    R43CA200398
  • Full Project Number
    3R43CA200398-01A1S1
  • Serial Number
    200398
  • FOA Number
    PA-15-269
  • Sub Project Id
  • Project Start Date
    6/7/2016 - 8 years ago
  • Project End Date
    9/6/2017 - 7 years ago
  • Program Officer Name
    LOU, XING-JIAN
  • Budget Start Date
    6/7/2016 - 8 years ago
  • Budget End Date
    9/6/2017 - 7 years ago
  • Fiscal Year
    2017
  • Support Year
    01
  • Suffix
    A1S1
  • Award Notice Date
    1/11/2017 - 7 years ago
Organizations

Digital Analysis of Plasma miRNA populations in Pancreatic Cancer

? DESCRIPTION (provided by applicant): The demand for robust, reliable, and minimally invasive diagnostic technologies represents a pressing need in the early detection, stratification, and surveillance of aggressive cancers. Cell-free microRNAs (miRNAs) represent a novel class of biomarkers that have shown promise during initial studies and may have significant clinical utility. The ability to efficiently and accurately identify and quantify circulating miRNA populatins is challenging however, and current approaches fail to meet the requirements of high specificity, sensitivity, accessibility, and reproducibility necessary for widespread adoption in screening and monitoring applications. In this phase I SBIR application, RedVault Biosciences proposes to establish the feasibility of a novel multiplex diagnostic platform to characterize circulating cell free miRNA populations, specifically those miRNAs of immediate utility in pancreatic cancer diagnosis, stratification, and intervention. The broadly-enabling technology leverages novel advancements in advanced molecular genomics, synthetic biology, and digital nucleic acid analysis to significantly reduce current, complex laboratory workflows and provide quantitative, reproducible and clinically informative results. Successful development of this technology could provide fundamental information to positively affect miRNA research, disease management, and patient survival.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    49970
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:49970\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    REDVAULT BIOSCIENCES, LP
  • Organization Department
  • Organization DUNS
    079101125
  • Organization City
    HOUSTON
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    770275133
  • Organization District
    UNITED STATES